Severe infliximab-induced psoriasis treated with adalimumab switching.

BACKGROUND

Antitumor necrosis factor (anti-TNF) agents are a well-established treatment for various medical conditions, including psoriasis and psoriatic arthritis. However, anti-TNF agents may themselves induce psoriasis in some patients.

METHODS

The authors report two cases of patients with severe and refractory infliximab-induced psoriasis.

RESULTS

The patients had good clinical responses after switching to another TNF blocker.

CONCLUSION

For severe cases, infliximab withdrawal combined with conventional immunosuppressive psoriasis drugs or with adalimumab may be a therapeutic option.